Public health aspects of genetic screening for hereditary haemochromatosis in Australia

Australian and New Zealand Journal of Public Health

Volumn 26, Issue 6, 2002, Pages 518-524

  Gertig, Dorota M ^a   Fletcher, Ashley ^a   Hopper, John L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FERRITIN; TRANSFERRIN;

AGE; ALLELE; AUSTRALIA; BLOOD ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DNA DETERMINATION; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; FERRITIN BLOOD LEVEL; GENE FREQUENCY; GENETIC COUNSELING; GENETIC DISORDER; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOTYPE; HEALTH CARE COST; HEALTH PROMOTION; HEMOCHROMATOSIS; HUMAN; IRON ABSORPTION; IRON OVERLOAD; LIFE EXPECTANCY; MASS SCREENING; MORBIDITY; MORTALITY; PENETRANCE; PHLEBOTOMY; POPULATION RESEARCH; PROBABILITY; PUBLIC HEALTH; REVIEW; STANDARDIZATION; SURVIVAL; TRANSFERRIN BLOOD LEVEL;

EID: 0036967644     PISSN: 13260200     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1467-842X.2002.tb00360.x     Document Type: Review

References (60)

1. Powell LW, George DK, McDonnell SM, Kowdley KV. Diagnosis of hemochromatosis. Ann Intern Med 1998;129:925-31.
2. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
3. Cogswell ME, Burke W, McDonnell SM, Franks AL. Screening for hemochromatosis. A public health perspective. Am J Prev Med 1999;16:134-40.
4. Niederau C, Strohmeyer G. Strategies for early diagnosis of haemochromatosis. Eur J Gastroenterol Hepatol 2002;14:217-21.
5. Press RD. Hereditary hemochromatosis: Impact of molecular and iron-based testing on the diagnosis, treatment, and prevention of a common, chronic disease. Arch Pathol Lab Med 1999;123:1053-9.
6. Guide to clinical preventive services. In: US Preventive Services Task Force. 2nd ed. Baltimore: Williams Wilkins; 1996.
7. Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2002;94:1221-6.
8. Piperno A, Sampietro M, Pietrangelo A, Arosio C, et al. Heterogeneity of hemochromatosis in Italy. Gastroenterology 1998;114:996-1002.
9. Jazwinska EC, Cullen LM, Busfield F, Pyper W, et al. Haemochromatosis and HLA-H [letter; comment]. Nat Genet 1996;14:249-51.
10. Willis G, Jennings BA, Goodman E, Fellows IW, Wimperis JZ. A high prevalence of HLA-H 845A mutations in hemochromatosis patients and the normal population in eastern England. Blood Cells Mol Dis 1997;23:288-91.
11. Burke W, Imperatore G, McDonnell SM, Baron RC, Khoury MJ. Contribution of different HFE genotypes to iron overload disease: A pooled analysis. Genet Med 2000;2:271-7.
12. Lester S, Bardy P, McCluskey J. HFE genotypes and haemochromatosis: Quantifying the risk of disease. Tissue Antigens 1999;54:282-4.
13. Yang Q, McDonnell SM, Khoury MJ, Cono J, Parrish RG. Hemochromatosis-associated mortality in the United States from 1979 to 1992: An analysis of Multiple-Cause Mortality Data. Ann Intern Med 1998;129:946-53.
14. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-24.
15. Bomford A, Williams R. Long term results of venesection therapy in idiopathic haemochromatosis. Q J Med 1976;45:611-23.
16. Bradley LA, Haddow JE, Palomaki GE. Population screening for haemochromatosis: A unifying analysis of published intervention trials. J Med Screen 1996;3:178-84.
17. Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000;133:329-37.
18. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→ A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-8.
19. Moirand R, Adams PC, Bicheler V, Brissot P, Deugnier Y. Clinical features of genetic hemochromatosis in women compared with men. Ann Intern Med 1997;127:105-10.
20. Leggett BA, Brown NN, Bryant SJ, Duplock L, Powell LW, Halliday JW. Factors affecting the concentrations of ferritin in serum in a healthy Australian population. Clin Chem 1990;36:1350-5.
21. Leggett BA. Iron in an Australian population: Too little or too much? J Gastroenterol Hepatol 1996;11:1037-9.
22. Whitfield JB, Cullen LM, Jazwinska EC, Powell LW, et al. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am J Hum Genet 2000;66:1246-58.
23. Andrews NC. Iron homeostasis: Insights from genetics and animal models. Nat Rev Genet 2000;1:208-17.
24. Powell LW, Subramaniam VN, Yapp TR. Haemochromatosis in the new millennium. J Hepatol 2000;32:48-62.
25. Barton JC, Bottomley SS. Iron deficiency due to excessive therapeutic phlebotomy in hemochromatosis. Am J Hematol 2000;65:223-6.
26. Williams R, Smith PM, Spicer EJ, Barry M, Sherlock S. Venesection therapy in idiopathic haemochromatosis. An analysis of 40 treated and 18 untreated patients. Q J Med 1969;38:1-16.
27. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19.
28. Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology 1991;101:368-72.
29. Trent RJ, Le H, Yu B, Young G, Bowden DK. DNA testing for haemochromatosis: Diagnostic, predictive and screening implications. Pathology 2000;32:274-9.
30. Feldman W. How serious are the adverse effects of screening? J Gen Intern Med 1990;5:S50-3.
31. Power TE, Adams PC. Psychosocial impact of C282Y mutation testing for hemochromatosis. Genet Test 2001;5:107-10.
32. Alper JS, Geller LN, Barash CI, Billings PR, Laden V, Natowicz MR. Genetic discrimination and screening for hemochromatosis. J Public Health Policy 1994;15:345-58.
33. Barash CI. Genetic discrimination and screening for hemochromatosis: Then and now. Genet Test 2000;4:213-8.
34. Delatycki M, Allen K, Williamson R. Insurance agreement to facilitate genetic testing. Lancet 2002;359:1433.
35. Bassett ML, Leggett BA, Halliday JW, Webb S, Powell LW. Analysis of the cost of population screening for haemochromatosis using biochemical and genetic markers. J Hepatol 1997;27:517-24.
36. Burke W, Thompson E, Khoury MJ, McDonnell DM, et al. Hereditary hemochromatosis: Gene discovery and its implications for population-based screening. J Am Med Assoc 1998;280:172-8.
37. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000;33:485-504.
38. Cullen LM, Summerville L, Glassick TV, Grawford DH, Powell LW, Jazwinska EC. Neonatal screening for the hemochromatosis defect [Letter]. Blood 1997;90:4236-7.
39. Cullen LM, Gao X, Easteal S, Jazwinska EC. The hemochromatosis 845 G→A and 187 C→G mutations: Prevalence in non-Caucasian populations. Am J Hum Genet 1998;62:1403-7
40. Rossi E, Henderson S, Chin CY, Olynyk J, et al. Genotyping as a diagnostic aid in genetic haemochromatosis. J Gastroenterol Hepatol 1999;14:427-30.
41. Takeuchi T, Soejima H, Faed JM, Yun K. Efficient large-scale screening for the hemochromatosis susceptibility gene mutation [letter]. Blood 1997;90:2848-9.
42. Burt MJ, George PM, Upton JD, Collett JA, et al. The significance of haemochromatosis gene mutations in the general population: Implications for screening. Gut 1998;43:830-6.
43. Distante S, Berg JP, Lande K, Haug E, Bell H. High prevalence of the hemochromatosis-associated Cys282Tyr HFE gene mutation in a healthy Norwegian population in the city of Oslo, and its phenotypic expression. Scand J Gastroenterol 1999;34:529-34.
44. Guttridge MG, Carter K, Warwood M, Darke C. Population screening for hemochromatosis by PCR using sequence-specific primers. Genet Test 2000;4:111-4.
45. Merryweather-Clarke AT, Worwood M, Parkinson L, Mattock C, et al. The effect of HFE mutations on serum ferritin and transferrin saturation in the Jersey population. Br J Haematol 1998;101:369-73.
46. Mura C, Raguenes O, Ferec C. HFE mutations analysis in 711 hemochromatosis probands: Evidence for S65C implication in mild form of hemochromatosis. Blood 1999;93:2502-5.
47. Murphy S, Curran MD, McDougall N, Callendere ME, O'Brien CJ, Middleton D. High incidence of the Cys 282 Tyr mutation in the HFE gene in the Irish population - Implications for haemochromatosis. Tissue Antigens 1998;52:484-8.
48. Simonsen K, Dissing J, Rudbeck L, Schwartz M. Rapid and simple determination of hereditary haemochromatosis mutations by multiplex PCR-SSCP: Detection of a new polymorphic mutation. Ann Hum Genet 1999;63:193-7.
49. Longo F, Zecchina G, Sbaiz L, Fischer R, Piga A, Camaschella C. The influence of hemochromatosis mutations on iron overload of thalassemia major. Haematologica 1999;84:799-803.
50. Restagno G, Gomez AM, Sbaiz L, De Gobbi M, et al. A pilot C282Y hemochromatosis screening in Italian newborns by TaqMan technology. Genet Test 2000;4:177-81.
51. Cassaneli S, Pignatti E, Montosi G, Garuti C, et al. Frequency and biochemical expression of C282Y/H63D hemochromatosis (HFE) gene mutations in the healthy adult population in Italy. J Hepatol 2001;34:523-8.
52. Campo S, Restuccia T, Villari D, Raffa G, et al. Analysis of haemochromatosis gene mutations in a population from the Mediterranean Basin. Liver 2001;21:233-6.
53. Sanchez M, Bruguera M, Bosch J, Rodes J, Ballesta F, Oliva R. Prevalence of the Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary hemochromatosis and in controls. J Hepatol 1998;29:725-8.
54. Steinberg KK, Cogswell ME, Chang JC, Caudill SP, et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. J Am Med Assoc 2001;285:2216-22.
55. Bradley LA, Johnson DD, Palomaki GE, Haddow JE, Robertson NH, Ferrie RM. Hereditary haemochromatosis mutation frequencies in the general population. J Med Screen 1998;5:34-6.
56. McDonnell SM, Hover A, Gloe D, Ou CY, Cogswell ME, Grummer-Strawn L. Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri. Am J Med 1999;107:30-7.
57. Chang JG, Liu TC, Lin SF. Rapid diagnosis of the HLA-H gene Cys 282 Tyr mutation in hemochromatosis by polymerase chain reaction - A very rare mutation in the Chinese population [letter]. Blood 1997;89:3492-3.
58. Lee JY, Yoo KH, Hahn SH. HFE gene mutation, C282Y causing hereditary hemochromatosis in Caucasians is extremely rare in Korean population. J Korean Med Sci 2000;15:179-82.
59. Sohda T, Yanai J, Soejima H, Tamura K. Frequencies in the Japanese population of HFE gene mutations. Biochem Genet 1999;37:63-8.
60. Gochee PA, Powell LW, Cullen DJ, DuSart D, Rossi E, Olynyk JK. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterol 2002;122:646-51.